Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-11,750,000
Closed -$173M 89
2025
Q3
$173M Buy
+11,750,000
New +$120M 0.97% 22
2023
Q4
Sell
-30,000
Closed -$463K 119
2023
Q3
$463K Buy
30,000
+7,500
+33% +$126K ﹤0.01% 108
2023
Q2
$426K Sell
22,500
-47,500
-68% -$834K ﹤0.01% 119
2023
Q1
$1.07M Buy
+70,000
New +$913K 0.01% 119
2022
Q3
Sell
-220,000
Closed -$708K 162
2022
Q2
$708K Buy
220,000
+205,000
+1,367% +$619K 0.01% 152
2022
Q1
$57K Sell
15,000
-85,000
-85% -$548K ﹤0.01% 163
2021
Q4
$1.31M Buy
100,000
+4,000
+4% +$63.2K 0.01% 160
2021
Q3
$1.88M Hold
96,000
0.02% 148
2021
Q2
$1.79M Buy
96,000
+1,000
+1% +$22.3K 0.01% 171
2021
Q1
$2.25M Buy
95,000
+2,000
+2% +$46.2K 0.02% 166
2020
Q4
$2.27M Hold
93,000
0.03% 118
2020
Q3
$2.39M Buy
+93,000
New +$2.95M 0.03% 114

Other funds holding ETNB

Pentwater Capital Management's ETNB Position: Q4 2025 in Review

Pentwater Capital Management sold out of 89bio (ETNB) in Q4 2025, closing a stake of 11,750,000 shares — an estimated $173M sold.

Pentwater Capital Management first reported a position in ETNB in Q3 2020 and held it in 12 quarters. The position peaked at $173M in Q3 2025. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.

  • Pentwater Capital Management reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
  • Pentwater Capital Management sold 11,750,000 89bio shares in Q4 2025, an estimated $173M.
  • Pentwater Capital Management first reported a position in 89bio in Q3 2020 and held it in 12 quarters.
  • Pentwater Capital Management's 89bio position peaked at $173M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.

Based on Pentwater Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.